Pharmaceutical Japanese drug major Eisai (TYO: 4523) announced results from a pivotal Phase III clinical trial (Study 304) of Fycompa (perampanel), the first in a new class of adjunctive treatment in people with partial-onset seizures, with or without secondary generalized seizures, aged 12 years and older. This showed that once-daily, adjunctive perampanel at doses of 8mg or 12mg improved seizure control in people with uncontrolled partial-onset seizures, and that both doses had an acceptable safety and tolerability profile. 27 July 2012